Pneumococcal protein vaccines – affordability, availability and use in developing countries
Dr Mark Alderson, Director, Pneumococcal Vaccine Project, Vaccine Development Global Program at PATH, discussed the progress on pneumococcal protein vaccines – affordability, availability and use in developing countries.
Watch his presentation from the 10th annual World Vaccine Congress Washington now for free.
- Developing a portfolio of potential vaccine candidates with a particular emphasis on “common protein” vaccines – common to all pneumococcal serotypes
- Current protein vaccine partnerships range from novel methods of antigen discovery to well characterized vaccine candidates that have provided protection in multiple animal models and early stages of clinical evaluation
- Second strategy involves development of a killed, whole cell vaccine, also designed to offer broad serotype-independent coverage coupled with low manufacturing costs and ease of administration.
- Exploring strategies to incorporate common protein antigens into a limited valency pneumococcal conjugate vaccine (PCV)
- Advantages to the regulatory path established for licensure of new PCVs and offering further benefit of broader coverage by adding a pneumococcal protein antigen